The FDA has approved pembrolizumab (Keytruda) plus gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.
Related Keywords
California , United States , San Francisco , Merck Keytruda , Robin Kate Kelley , University Of California , Kate Kelley , Pembrolizumab , Gastrointestinal ,
vimarsana.com © 2020. All Rights Reserved.